Surufatinib

Generic Name: Surufatinib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₈N_₆O_₃S

CAS Number: 1308672-74-3

Unique Ingredient Identifier: B2K5L1L8S9

Background: Surufatinib is under investigation in clinical trial NCT02588170 (Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors).

Indication: 单药用于治疗无法手术切除的局部晚期或转移性、进展期非功能性、分化良好（G1、G2）的胰腺和非胰腺来源的神经内分泌瘤（pNETs）。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Study to Assess the Effect of a Strong CYP3A Inhibitor, on Surufatinib in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Surufatinib
Drug: Itraconazole

First Posted Date: 2020-05-04

Last Posted Date: 2021-02-03

Lead Sponsor: Hutchison Medipharma Limited

Target Recruit Count: 13

Registration Number: NCT04372407

Locations: 🇺🇸
Covance Clinical Research Unit, Dallas, Texas, United States

A Study to Assess the Effect of a High Fat Meal on Surufatinib in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: surufatinib

First Posted Date: 2020-05-04

Last Posted Date: 2021-05-24

Lead Sponsor: Hutchison Medipharma Limited

Target Recruit Count: 28

Registration Number: NCT04372394

Locations: 🇺🇸
Covance Clinical Research Unit, Dallas, Texas, United States

Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors

Phase 2

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: Surufatinib
Drug: Toripalimab

First Posted Date: 2019-11-20

Last Posted Date: 2023-03-02

Lead Sponsor: Hutchison Medipharma Limited

Target Recruit Count: 248

Registration Number: NCT04169672

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients

Phase 2

Conditions: Biliary Tract Cancer

Interventions: Drug: Surufatinib
Drug: Capecitabine

First Posted Date: 2019-03-13

Last Posted Date: 2020-02-13

Lead Sponsor: Hutchison Medipharma Limited

Target Recruit Count: 298

Registration Number: NCT03873532

Locations: 🇨🇳
PLA 307 Hospital, Beijing, Beijing, China

Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma

Phase 2

Completed

Conditions: Biliary Tract Cancer

Interventions: Drug: Surufatinib

First Posted Date: 2016-11-17

Last Posted Date: 2019-02-27

Lead Sponsor: Hutchison Medipharma Limited

Target Recruit Count: 39

Registration Number: NCT02966821

Locations: 🇨🇳
The 307th Hospital of Military Chinese People's Liberation Army, Beijing, Beijing, China
🇨🇳
Heilongjiang Cancer Hospital, Ha'erbin, Heilongjiang, China
🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

and more 2 locations

Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma

Phase 2

Completed

Conditions: Thyroid Carcinoma

Interventions: Drug: Surufatinib

First Posted Date: 2015-11-25

Last Posted Date: 2020-02-13

Lead Sponsor: Hutchison Medipharma Limited

Target Recruit Count: 66

Registration Number: NCT02614495

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors

Phase 3

Completed

Conditions: Neuroendocrine Tumors

Interventions: Other: Placebo
Drug: Surufatinib

First Posted Date: 2015-10-28

Last Posted Date: 2023-03-30

Lead Sponsor: Hutchison Medipharma Limited

Target Recruit Count: 195

Registration Number: NCT02589821

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

and more 2 locations

Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors

Phase 3

Completed

Conditions: Neuroendocrine Tumors

Interventions: Other: Placebo
Drug: Surufatinib

First Posted Date: 2015-10-27

Last Posted Date: 2023-03-30

Lead Sponsor: Hutchison Medipharma Limited

Target Recruit Count: 219

Registration Number: NCT02588170

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳
the 307 Hospital of People's Liberation Army, Beijing, Beijing, China
🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

and more 2 locations

A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Tumors

Interventions: Drug: surufatinib

First Posted Date: 2015-09-15

Last Posted Date: 2024-07-10

Lead Sponsor: Hutchmed

Target Recruit Count: 130

Registration Number: NCT02549937

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Rocky Mountain Cancer Center, Denver, Colorado, United States
🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States

and more 9 locations

A Food Effect Phase I Study of the Sulfatinib in Healthy Subjects (HMPL-012)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Sulfatinib

First Posted Date: 2014-12-19

Last Posted Date: 2020-05-08

Lead Sponsor: Hutchison Medipharma Limited

Target Recruit Count: 24

Registration Number: NCT02320409

Locations: 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, Shanghai, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy